Veracyte (VCYT) reported late Monday its Q4 non-GAAP earnings of $0.36 per diluted share, up from $0.21 a year earlier.

Analysts polled by FactSet expected $0.27.

Revenue for the quarter that ended Dec. 31 was $118.6 million, up from $98.2 million a year earlier.

Analysts surveyed by FactSet expected $116.7 million.

For 2025, the company said it expects testing revenue of $470 million to $480 million.

Given the number of variables impacting its Marseille, France operations, Veracyte said it is not providing total revenue outlook at this time and would provide the guidance once there is more clarity on the timing and impact of the process.

Shares of Veracyte were down over 6% in after-hours activity.